Article
MicroRNA‐guided drug discovery for mitigating persistent pulmonary complications in critical COVID‐19 survivors: A longitudinal pilot study
15 Feb 2024
Abstract excerpt
BACKGROUND AND PURPOSE: The post-acute sequelae of SARS-CoV-2 infection pose a significant global challenge, with nearly 50% of critical COVID-19 survivors manifesting persistent lung abnormalities. The lack of understanding about the molecular mechanisms and effective treatments hampers their management. Here, we employed microRNA (miRNA) profiling to decipher the systemic molecular underpinnings of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
